Company
Headquarters: Cambridge, MA, United States
Employees: 274
CEO: Mr. Nick Leschly
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $100.4 M |
| EBITDA | $-206,418,000 |
| Gross Profit TTM | $83.5 M |
| Profit Margin | -216.73% |
| Operating Margin | -560.47% |
| Quarterly Revenue Growth | -81.00% |
2seventy bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TSVT wb_incandescent